Abiraterone after Enzalutamide?

Hi S20,

My husband is on Arbiterone for stage 4 pc with mets in both lungs, bones and lymph nodes. Doing well on it for one year but side effects are troublesome. He won’t be offered chemotherapy they say. This with the hormone therapy is his only treatment. It’s Good that your PSA is stable and although I don’t have an exact answer to your question I think you should be considered for it at least. 
No harm in asking for it. I most certainly will be asking for enzalutamide when or if it stops working 

Good luck with it … following too.. 

much love from Louli

Hi Sussex, I've been on Enzalutamide and Zolodex since February 2021, and am now asking the question, what happens when the cancer becomes tolerant to these drugs, I should ask my oncologist when I next meet with him/her?. I always thought that Abiraterone was the alternative to enzalutamide. 

At the moment my PSA is virtually untraceable 0.003 which is good but I know it's going to change some time and wonder how you felt when things changed. all the best in your treatment. Del. of Sussex

Hi, I've been on Zoladex since June 2020 and my PSA atm is a pleasing 0.61. I have the same question as to what happens when the cancer finds another way to avoid the zoladex, and my PSA starts to rise? Anyone had experience of this? Any info gratefully appreciated.

Best wishes to all.

Bas

NHS doesn't allow the use of more than one of the novel hormone therapy drugs (Enzalutamide, Daralutamide, Apalutamide, Abriaterone) during teatment, except as part of a trial, or in the case of unacceptable side effects in the first 3 months. The official reason given is that when one fails, the others don't work either. In other countries, it does appear that there is some truth in this, but serial use (switching to another when one fails) does help a few people. Another factor was undoubtedly the cost - these are very expensive. However, Abiraterone's patent has just expired in the UK, so unbranded Abiraterone is now available and presumably much cheaper, so this could result in a change in this area. Enzalutamide's UK patent doesn't have long left to run either.